Citius Oncology, Inc.
CTOR
$0.69
$0.011.16%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 87.47% | -9.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 95.19% | -4.72% | |||
| Operating Income | -11.48% | 4.72% | |||
| Income Before Tax | -11.36% | 7.31% | |||
| Income Tax Expenses | 0.00% | 0.00% | |||
| Earnings from Continuing Operations | -10.76% | 6.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.76% | 6.95% | |||
| EBIT | -11.48% | 4.72% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 0.63% | 15.07% | |||
| Normalized Basic EPS | 0.00% | 15.47% | |||
| EPS Diluted | 0.63% | 15.07% | |||
| Normalized Diluted EPS | 0.00% | 15.47% | |||
| Average Basic Shares Outstanding | 11.54% | 9.59% | |||
| Average Diluted Shares Outstanding | 11.54% | 9.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||